Chemerin is recently identified adipose hormone, which plays a role in adipogenesis, energy metabolism and inflammation. Increased levels of chemerin have been linked to obesity and development of diabetes mellitus. During the transition from premenopause to postmenopause, many women experience weight gain and central fat deposition, hence we hypothesized that circulating level of chemerin can play a role in the pathogenesis of hypertension and cardiometabolic risk in postmenopausal females.Design and method:
Methods: The study included 80 women (mean age 57.6 ± 5.4 years), 54 subjects with arterial hypertension and 26 normotensive age matched controls. In all subjects anthropometrical measurements and 24-hr ABPM were performed. Fasting blood samples were taken for glucose, insulin and serum lipids concentration. Serum levels of chemerin, nesfatin and obestatin were measured using an immunochemical assay. Asymptomatic organ damages were analyzed including echocardiographic examination with assessment of left ventricular mass (LVM), (GE Vivid 7.0); carotid ultrasound with measurement of intima-media thickness (IMT), and carotid-femoral pulse wave velocity measurement(PWV) (Sphygmocor).Results:
Results: Compared with controls, subjects with hypertension had higher serum chemerin levels (147,8 ± 29,7 vs 132,2 ± 23,6; p = 0,05). Nesfatin and obestatin concentrations did not differ between hypertensive and normotensive groups. Chemerin was significantly associated with metabolic characteristics including BMI (r = 0,32, p = 0,003), waist circumference (r = 0,48, p = 0,0001), fasting glucose (r = 0,27, p = 0,02), and triglycerides (r = 0,20, p = 0.07). In logistic regression analysis, chemerin concentration was an independent predictor of the presence of hypertension, but the association lost its significance after adjustment for BMI.Conclusions:
Conclusions: In postmenopausal women serum chemerin is independently associated with left ventricular mass, left atrial volume and components of metabolic syndrome. Association of chemerin with hypertension is mediated by body adiposity.